Abstract: Provided is a method of producing a novel microorganism having a minimal genome. In particular, provided are a method of producing a novel microorganism having a smaller genome size than a wild-type, the method including the step of culturing the microorganism in a medium containing LB broth with stepwise decreasing concentrations of the LB broth; and a novel microorganism having a smaller genome size than a wild-type, produced by the above method. Despite the small genome size, the novel microorganism of the present disclosure may have a high growth rate, pyruvate production capacity, and protein translation efficiency thereby being usefully applied to industry such as production of recombinant proteins or pyruvate.

Abstract: Provided are a recombinant yeast having improved ability to produce ginsenoside, which is prepared by overexpressing INO2 and INO4 or deleting OPT1 in a yeast having ability to produce ginsenoside, a method of preparing the yeast, and a method of producing ginsenoside by using the yeast.

Abstract: The present invention relates to recombinant yeast, in which the productivity of ginsenoside is enhanced by overexpressing CPR5, PDI1, or ERO1 in yeast having the productivity of ginsenosides; a method for preparing the yeast; and a method for producing ginsenosides using the yeast.

Abstract: The present invention relates to a pharmaceutical composition, a health functional food, and a feed composition for the prevention, improvement, or treatment of non-alcoholic liver disease or insulin resistance comprising ginsenoside F2. The pharmaceutical composition according to the present invention comprising ginsenoside F2 can inhibit the adipogenesis and lipid accumulation in the liver, improve insulin sensitivity, inhibit the expression of inflammatory cytokines such as TNF-?, IL-?, and IL-6 in the Kupffer cell, inhibit the expression of endocannabinoid synthase, thus capable of effectively preventing or treating non-alcoholic liver disease or insulin resistance.

Abstract: Provided are a recombinant yeast having improved ability to produce ginsenoside, which is prepared by overexpressing INO2 and INO4 or deleting OPT1 in a yeast having ability to produce ginsenoside, a method of preparing the yeast, and a method of producing ginsenoside by using the yeast.

Abstract: Provided is a method of producing a novel microorganism having a minimal genome. In particular, provided are a method of producing a novel microorganism having a smaller genome size than a wild-type, the method including the step of culturing the microorganism in a medium containing LB broth with stepwise decreasing concentrations of the LB broth; and a novel microorganism having a smaller genome size than a wild-type, produced by the above method. Despite the small genome size, the novel microorganism of the present disclosure may have a high growth rate, pyruvate production capacity, and protein translation efficiency thereby being usefully applied to industry such as production of recombinant proteins or pyruvate.

Abstract: The present invention relates to compositions for enhancing innate immunity, comprising ginsenoside F1 as an active ingredient. Specifically, the composition according to the present invention promotes degranulation activity and cell-killing activity of natural killer cells, and increases expressions of cell-killing factors, thereby being effectively used as an innate immunity enhancer.

Abstract: The present invention relates to yeast with an enhanced ginsenoside-producing ability prepared by changing Ald2, Ald6, Zwf1, and Zms1, a method of preparing the yeast, and a method for producing ginsenosides using the yeast.

Abstract: The present invention provides an antimicrobial peptide polymer comprising at least one monomer which is digested by pepsin, a multimeric antimicrobial peptide complex comprising the polymer and a cell surface anchoring motif linked to the polymer, an antimicrobial microorganism displaying the multimeric antimicrobial peptide complex, an antimicrobial composition comprising the same, a method of treating an infectious disease caused by bacteria, yeast or fungi by administering the antimicrobial composition, and a method for producing the antimicrobial microorganism. According to the invention, living microorganisms displaying an antimicrobial peptide on the cell surface thereof may be administered in vivo without having to lyse the microbial cell and isolate and purify the antimicrobial peptide, so that the antimicrobial peptide exhibits antimicrobial activity. Thus, the antimicrobial peptide may be produced at significantly reduced costs so that it may have widespread use.

Abstract: The present invention relates to a pharmaceutical composition containing ginsenoside F1 or Rh1 for preventing or treating vascular leak syndrome, to a method for treating vascular leak syndrome using the pharmaceutical composition, and to a food composition containing ginsenoside F1 or Rh1 for preventing or ameliorating vascular leak syndrome. The ginsenoside F1 or Rh1 provided in the present invention can promote angiogenesis and suppress vascular leakage, and thus can be widely utilized in the effective prevention or treatment of vascular leak syndrome.

Abstract: Provided are a pharmaceutical composition for preventing or treating cervical cancer including gypenoside LXXV or a pharmaceutically acceptable salt thereof as an active ingredient, a method of preventing or treating cervical cancer including administering the pharmaceutical composition to a subject excluding humans, a health functional food composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient, and a feed composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Gleevec-resistant leukemia, containing, as an active ingredient, ginsenoside F1 or Rg3 which exhibits a preventive or therapeutic effect on Gleevec-resistant leukemia through enhancing cell killing activity of NK cells; a method for treating Gleevec-resistant leukemia comprising a step of administering the pharmaceutical composition; and a food composition for preventing or ameliorating Gleevec-resistant leukemia. Since the pharmaceutical composition of the present invention can effectively treat leukemia that exhibits resistance to conventional Gleevec, the pharmaceutical composition can be widely used for effective leukemia treatment.

Abstract: The present invention relates to a composition for wound healing or skin regeneration comprising gypenoside 75 (gypenoside LXXV) as an active ingredient.

Abstract: The present invention relates to a method for preparing an antimicrobial peptide with enhanced adhesion, and an antimicrobial coating method of the antimicrobial peptide with enhanced adhesion. The antimicrobial coating method of the present invention can be widely used as a method for adding an antimicrobial property to medical products and industrial products, because the method is capable of coating the antimicrobial peptide with enhanced adhesion, which has no cytotoxicity and possesses an excellent antimicrobial activity, on various surfaces with optimal efficiency.

Abstract: The present invention relates to a method for screening an activator of mitochondrial activity by using gypenoside-treated cells, to a composition for screening an activator of mitochondrial activity, comprising the gypenoside, and to a kit comprising the composition. By using the method for screening an activator of mitochondrial activity of the present invention, it is possible to effectively discover a preparation which can substantially promote the mitochondrial activity, and thus the method is expected to be widely used in developing a therapeutic agent for diseases caused by mitochondrial activity inhibition.

Abstract: Provided are a food composition and a feed composition for removing amyloid plaques, each composition including ginsenoside F1, in which ginsenoside F1 is effective for removing amyloid plaques in the hippocampal area of the brain.

Abstract: Provided is a method of preparing cinnamaldehyde by using a recombinant microorganism.

Abstract: Provided are a composition for solubilizing a target protein, including an expression cassette including a promoter and a gene encoding a fusion protein of a chaperone and an RNA-binding domain or an expression vector including the expression cassette; a transformant including the expression cassette or the expression vector; a kit including the composition or the transformant; and a method for producing the target protein by using the same.

Abstract: The present invention relates to a method for mass production of ginsenoside Rh2-Mix. The present invention includes treating PPD-Mix with an organic acid and heat to obtain Rg3-Mix and treating the obtained Rg3-Mix using a recombinant GRAS strain in the Rg3-Mix to produce Rh2-Mix, and thereby facilitates the mass production of ginsenoside Rh2-Mix using ?-glucosidase, which has been known to be difficult. Further, the present invention is advantageous in that the Rh2-Mix can be produced in high yield even at high temperatures, and mass production thereof for industrial purposes is practical as the production process is simple and more economical than direct use of an enzyme.

Abstract: The present invention relates to recombinant yeast, in which the productivity of ginsenoside is enhanced by overexpressing CPR5, PDI1, or ERO1 in yeast having the productivity of ginsenosides; a method for preparing the yeast; and a method for producing ginsenosides using the yeast.